Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases
David Cheng, Bharati Kochar, Tianxi Cai, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 10, pp. 2366-2372.e6
Open Access | Times Cited: 25

Showing 25 citing articles:

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Virginia Solitano, Antonio Facciorusso, Tine Jess, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 4, pp. 907-921.e2
Closed Access | Times Cited: 54
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Danijela Tatović, Ashish Marwaha, Peter Taylor, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2657-2666
Open Access | Times Cited: 9
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 6
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Complications virales des biothérapies/thérapies ciblées anti-inflammatoires
Lionel Piroth, Florian Moretto, Thibault Sixt, et al.
La Revue de Médecine Interne (2025)
Open Access
Prioritization in inflammatory bowel disease therapy
Klaus Herrlinger, Eduard F. Stange
Expert Review of Gastroenterology & Hepatology (2023) Vol. 17, Iss. 8, pp. 753-767
Closed Access | Times Cited: 10
Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study
Teresa Valdés Delgado, Olmedo Martín Rául, Marisa Iborra, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 8
Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study
Katsuyoshi Ando, Mikihiro Fujiya, Nobuhiro Ueno, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 2
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
Daniela Pugliese, Giuseppe Privitera, Marcello Fiorani, et al.
Therapeutic Advances in Gastroenterology (2022) Vol. 15
Open Access | Times Cited: 13
Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study
Min Jee Kim, Ye‐Jee Kim, Daehyun Jeong, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 2
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab
Maryia Zhdanava, Ruizhi Zhao, Ameur M. Manceur, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 8, pp. 907-916
Open Access | Times Cited: 6
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults
Sophie Vieujean, Édouard Louis, Silvio Danese, et al.
Expert Review of Gastroenterology & Hepatology (2023) Vol. 17, Iss. 5, pp. 413-430
Closed Access | Times Cited: 5
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
María Antonietta Barbieri, Anna Viola, Giuseppe Cicala, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3280-3280
Open Access | Times Cited: 9
Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis
Rahul Masson, Justine R. Seivright, Tristan Grogan, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 7, pp. 1901-1916
Open Access | Times Cited: 1
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
Talat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 61-69
Closed Access | Times Cited: 4
Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine
Mariam S Mukhtar, Mahmoud Mosli
Saudi Journal of Gastroenterology (2024) Vol. 30, Iss. 3, pp. 126-137
Open Access
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn’s Disease Patients
Gerum Gashaw Gebeyehu, Giacomo Broglio, Eleanor Liu, et al.
Inflammatory Bowel Diseases (2024)
Closed Access
Detection of risk signals for ustekinumab in the real world using the FDA adverse event reporting system (FAERS)
Yi Zhao, Zelin Li, Kanghuai Zhang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Treatment Related Adverse Events and Monitoring of Patients Receiving Biologic or Small Molecule Therapy for Inflammatory Bowel Disease
Michael G. Stewart
Canadian IBD Today (2024)
Closed Access
Infections in psoriatic arthritis: association with treatment
Athanasios Vassilopoulos, Κonstantinos Thomas, Dimitrios Vassilopoulos
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent
Maryia Zhdanava, Sumesh Kachroo, Ameur M. Manceur, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 8, pp. 770-777
Closed Access | Times Cited: 1
Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report
Luiz Euribel Prestes-Carneiro, Marilda Aparecida Milanêz Morgado de Abreu, Eduardo Vinícius Mendes Roncada, et al.
Pathogens (2023) Vol. 12, Iss. 9, pp. 1156-1156
Open Access | Times Cited: 1
Ablative Treatment of Inflammatory and Other Diseases With Monoclonal Antibodies (Mabs) or Janus Kinases (Nibs) Increases Risk for Infection
Eric Santana, Ken S. Rosenthal
Infectious Diseases in Clinical Practice (2023) Vol. 31, Iss. 6
Closed Access | Times Cited: 1
Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
Stephanie L. Gu, Sandy Simcha Nath, Alina Markova
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1610-1610
Open Access | Times Cited: 1
Themen – Stellungnahme zur Nutzenbewertung von Risankizumab (Morbus Crohn, vorbehandelte Patient*innen) vom 24. April 2023

Zeitschrift für Gastroenterologie (2023) Vol. 61, Iss. 06, pp. 747-751
Closed Access
Page 1

Scroll to top